FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3138935984> ?p ?o ?g. }

• W3138935984 abstract "Abstract Background As a tissue-specific proangiogenic or antiangiogenic agent, angiopoietin-like 4 (ANGPTL4) has recently gained attention in many diseases, such as metabolic syndrome, cardiovascular disease and cancer. However, the roles of ANGPTL4 in angiogenesis and tumor growth in epithelial ovarian cancer, the most lethal gynecologic malignancy, remain unclear. Objective To identify a novel mechanism of ANGPTL4 inhibition in epithelial ovarian cancer. Methods Western blot, quantitative reverse transcription PCR, and immunofluorescence analyses were applied to evaluate ANGPTL4 expression in ovarian cancer cell lines. Cell proliferation, migration, and invasion were investigated through 5-ethynyl-2′-deoxyuridine (EdU) incorporation, CCK-8 and Transwell assays. The expression of epithelial-mesenchymal transition (EMT)-related proteins in ovarian cancer cells and tumor-bearing mice was evaluated. CD31 staining was used to identify tumor angiogenesis. Immunoprecipitation was performed to examine the regulatory relationship between ANGPTL4 and the vascular endothelial growth factor receptor 2 (VEGFR2)/vascular endothelial (VE)-cadherin/Src complex. VEGFR2 phosphorylation at Y949 and VE-cadherin expression were assessed by western blotting. Inactivation of VEGFR2 Y949 phosphorylation was achieved in a MISIIR-TAg VEGFR2 Y949F/Y949F mouse model. Results Here, we demonstrated that ANGPTL4 was overexpressed in A2780 and CAOV3 ovarian cancer cells. In vitro assays indicated that inhibition of ANGPTL4 by lentiviral small interfering RNA does not alter ovarian cancer cell proliferation, migration, invasion, and EMT, while ANGPTL4 silencing exhibited significant inhibitory effects on tumor angiogenesis, growth, and metastasis in vivo. Immunoprecipitation analysis showed that suppression of ANGPTL4 was accompanied by dissociation of the VEGFR2/VE-cadherin/Src complex and phosphorylation of VEGFR2 Y949 in A2780 and CAOV3 ovarian tumors. Inactivation of VEGFR2 Y949 phosphorylation in MISIIR-TAg VEGFR2 Y949F/Y949F mice abolished all tumor-suppressive effects of ANGPTL4 inhibition in spontaneous ovarian carcinoma. Conclusions Overall, our results indicate that ANGPLT4 silencing delays tumor progression in specific types of ovarian cancer and may be a potential target for individualized treatment of ovarian cancer." @default.
• W3138935984 created "2021-03-29" @default.
• W3138935984 creator A5000875888 @default.
• W3138935984 creator A5025534715 @default.
• W3138935984 creator A5027529101 @default.
• W3138935984 date "2021-03-16" @default.
• W3138935984 modified "2023-09-27" @default.
• W3138935984 title "Deregulation of angiopoietin-like 4 slows ovarian cancer progression through vascular endothelial growth factor receptor 2 phosphorylation" @default.
• W3138935984 cites W1561814525 @default.
• W3138935984 cites W1573363574 @default.
• W3138935984 cites W1974975509 @default.
• W3138935984 cites W1978506033 @default.
• W3138935984 cites W1985635605 @default.
• W3138935984 cites W2000000541 @default.
• W3138935984 cites W2018643656 @default.
• W3138935984 cites W2024629474 @default.
• W3138935984 cites W2030537668 @default.
• W3138935984 cites W2031724207 @default.
• W3138935984 cites W2040593473 @default.
• W3138935984 cites W2066750311 @default.
• W3138935984 cites W2076633056 @default.
• W3138935984 cites W2081289494 @default.
• W3138935984 cites W2086073957 @default.
• W3138935984 cites W2090968329 @default.
• W3138935984 cites W2104366174 @default.
• W3138935984 cites W2107277218 @default.
• W3138935984 cites W2119584041 @default.
• W3138935984 cites W2121155498 @default.
• W3138935984 cites W2125561465 @default.
• W3138935984 cites W2126047917 @default.
• W3138935984 cites W2130572697 @default.
• W3138935984 cites W2142409504 @default.
• W3138935984 cites W2143358669 @default.
• W3138935984 cites W2146638343 @default.
• W3138935984 cites W2163838850 @default.
• W3138935984 cites W2233026563 @default.
• W3138935984 cites W2237017536 @default.
• W3138935984 cites W2438866487 @default.
• W3138935984 cites W2739549148 @default.
• W3138935984 cites W2764254762 @default.
• W3138935984 cites W2937159442 @default.
• W3138935984 cites W2940479320 @default.
• W3138935984 cites W2977400241 @default.
• W3138935984 cites W2981745349 @default.
• W3138935984 cites W3012695764 @default.
• W3138935984 cites W4211170507 @default.
• W3138935984 doi "https://doi.org/10.1186/s12935-021-01865-4" @default.
• W3138935984 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33726754" @default.
• W3138935984 hasPublicationYear "2021" @default.
• W3138935984 type Work @default.
• W3138935984 sameAs 3138935984 @default.
• W3138935984 citedByCount "10" @default.
• W3138935984 countsByYear W31389359842021 @default.
• W3138935984 countsByYear W31389359842022 @default.
• W3138935984 countsByYear W31389359842023 @default.
• W3138935984 crossrefType "journal-article" @default.
• W3138935984 hasAuthorship W3138935984A5000875888 @default.
• W3138935984 hasAuthorship W3138935984A5025534715 @default.
• W3138935984 hasAuthorship W3138935984A5027529101 @default.
• W3138935984 hasBestOaLocation W31389359841 @default.
• W3138935984 hasConcept C104317684 @default.
• W3138935984 hasConcept C121608353 @default.
• W3138935984 hasConcept C126322002 @default.
• W3138935984 hasConcept C167734588 @default.
• W3138935984 hasConcept C2777025900 @default.
• W3138935984 hasConcept C2779013556 @default.
• W3138935984 hasConcept C2779094623 @default.
• W3138935984 hasConcept C2780394083 @default.
• W3138935984 hasConcept C2780427987 @default.
• W3138935984 hasConcept C502942594 @default.
• W3138935984 hasConcept C55493867 @default.
• W3138935984 hasConcept C71924100 @default.
• W3138935984 hasConcept C77305985 @default.
• W3138935984 hasConcept C86803240 @default.
• W3138935984 hasConcept C96232424 @default.
• W3138935984 hasConceptScore W3138935984C104317684 @default.
• W3138935984 hasConceptScore W3138935984C121608353 @default.
• W3138935984 hasConceptScore W3138935984C126322002 @default.
• W3138935984 hasConceptScore W3138935984C167734588 @default.
• W3138935984 hasConceptScore W3138935984C2777025900 @default.
• W3138935984 hasConceptScore W3138935984C2779013556 @default.
• W3138935984 hasConceptScore W3138935984C2779094623 @default.
• W3138935984 hasConceptScore W3138935984C2780394083 @default.
• W3138935984 hasConceptScore W3138935984C2780427987 @default.
• W3138935984 hasConceptScore W3138935984C502942594 @default.
• W3138935984 hasConceptScore W3138935984C55493867 @default.
• W3138935984 hasConceptScore W3138935984C71924100 @default.
• W3138935984 hasConceptScore W3138935984C77305985 @default.
• W3138935984 hasConceptScore W3138935984C86803240 @default.
• W3138935984 hasConceptScore W3138935984C96232424 @default.
• W3138935984 hasIssue "1" @default.
• W3138935984 hasLocation W31389359841 @default.
• W3138935984 hasLocation W31389359842 @default.
• W3138935984 hasOpenAccess W3138935984 @default.
• W3138935984 hasPrimaryLocation W31389359841 @default.
• W3138935984 hasRelatedWork W2018643656 @default.
• W3138935984 hasRelatedWork W2049739326 @default.
• W3138935984 hasRelatedWork W2237017536 @default.
• W3138935984 hasRelatedWork W2358524972 @default.
• W3138935984 hasRelatedWork W2381595950 @default.

• next